Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Other Non-Current Assets (2021 - 2025)

Historic Other Non-Current Assets for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to $2.6 million.

  • Janux Therapeutics' Other Non-Current Assets fell 694.3% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 694.3%. This contributed to the annual value of $2.9 million for FY2024, which is 1494.62% up from last year.
  • Janux Therapeutics' Other Non-Current Assets amounted to $2.6 million in Q3 2025, which was down 694.3% from $2.7 million recorded in Q2 2025.
  • Janux Therapeutics' Other Non-Current Assets' 5-year high stood at $2.9 million during Q4 2024, with a 5-year trough of $140000.0 in Q3 2021.
  • In the last 5 years, Janux Therapeutics' Other Non-Current Assets had a median value of $2.4 million in 2023 and averaged $2.0 million.
  • Per our database at Business Quant, Janux Therapeutics' Other Non-Current Assets soared by 92357.14% in 2022 and then crashed by 694.3% in 2025.
  • Over the past 5 years, Janux Therapeutics' Other Non-Current Assets (Quarter) stood at $816000.0 in 2021, then skyrocketed by 70.34% to $1.4 million in 2022, then surged by 80.5% to $2.5 million in 2023, then grew by 14.95% to $2.9 million in 2024, then dropped by 8.91% to $2.6 million in 2025.
  • Its Other Non-Current Assets was $2.6 million in Q3 2025, compared to $2.7 million in Q2 2025 and $2.8 million in Q1 2025.